https://doi.org/10.5812/jjhs.118913

Bacillus Calmette-Guerin Vaccine-Associated Lymphadenitis in Children

authors:

avatar Ahmad Shamsizadeh 1 , 2 , * , avatar Roya Nikfar 2 , avatar Sina Nazari 2

Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Abuzar Children’s Medical Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Jundishapur Journal of Health Sciences: Vol.14, issue 1; e118913
published online: January 10, 2022
article type: Research Article
received: August 31, 2021
accepted: December 28, 2021

How To Cite Shamsizadeh A, Nikfar R, Nazari S. Bacillus Calmette-Guerin Vaccine-Associated Lymphadenitis in Children. Jundishapur J Health Sci. 2022;14(1):e118913. https://doi.org/10.5812/jjhs.118913.

Abstract

Background:

Tuberculosis (TB) is one of the most important infectious diseases worldwide. Bacillus Calmette-Guerin (BCG) is a live attenuated vaccine, entered into the childhood immunization program by the World Health Organization (WHO) in 1974 to prevent TB. One of the relatively common complications of BCG vaccination is regional lymphadenitis.

Objectives:

This study aimed to determine the lymphadenitis incidence in BCG-vaccinated children in southwest Iran.

Methods:

In a prospective descriptive study, infants born from March to June 2017 were evaluated for BCG vaccine complications at two, four, six, nine, and 12 months of age in Ahvaz, southwestern Iran.

Results:

The study enrolled 1,506 infants (794 males and 712 females). Among the vaccinated infants, four (0.26%) had injection site reactions, and 106 (7.03%) presented lymphadenitis (66 males and 40 females). The lymphadenitis rate was significantly higher in males than in females (P = 0.024). The mean age at presentation was 4.28 ± 0.79 months. Suppurative lymphadenitis was seen in 53 (50%) cases and nonsuppurative lymphadenitis in 53 (50%) cases. About 80% of nonsuppurative lymphadenitis resolved entirely or partially after a one-year follow-up. Of 53 cases with suppurative lymphadenitis, 46 (43.4%) developed spontaneous drainage, and seven (6.6%) were drained by needle aspiration. No significant relationship was found between the BCG inoculation site and lymphadenitis rate. No other complications such as osteomyelitis or disseminated BCG infection were observed after one year of follow-up.

Conclusions:

The relatively high incidence of BCG lymphadenitis in this study may be due to the vaccine strain, young vaccinees, and improper vaccination techniques. In most cases, nonsuppurative lymphadenitis regressed spontaneously, and suppurative lymphadenitis was drained spontaneously or by needle aspiration.

1. Background

The World Health Organization (WHO) estimates that tuberculosis (TB) is a leading cause of mortality and morbidity worldwide. An incidence of 10.4 million cases and 1.8 million TB-associated deaths were reported in 2015 (1). Bacillus Calmette-Guerin (BCG) was developed by two French investigators, Albert Calmette and Camille Guerin, from 1908 to 1921 by the subculture of Mycobacterium bovis every three weeks for 13 years, remaining the only currently licensed TB vaccine (2). The WHO approved BCG as a vaccine against TB in 1974 (3). The WHO reports that as many as 100 million children are given BCG vaccination each year (4). The BCG vaccine reduces the risk of pulmonary TB up to about 60% and has a significant effect of 80% in preventing meningitis and disseminated TB infection (5).

However, adverse events after BCG vaccination have been described since its introduction, which can be classified as localized or disseminated manifestations (3, 6). Adverse reactions are reported in up to 10% of vaccinees (7). Some local adverse reactions are reported following BCG vaccination, such as local ulceration, inoculation site abscess, keloid reaction, and regional lymphadenitis. Rarely systemic reactions such as osteomyelitis/osteitis and disseminated BCG infection are reported in immunodeficient children (5, 8, 9).

Simple BCG lymphadenitis will regress spontaneously over a few weeks without the need for any treatment. The suppurative form of BCG lymphadenitis can develop into spontaneous rupture and sinus formation, later healed by cicatrization (10). Needle aspiration is helpful in most cases to prevent these complications and hasten the healing process. Surgical excision is recommended only in case of draining sinus or failed needle aspiration due to multiloculated abscess (11-13). In Iran, BCG is routinely administered in the neonatal period under the National Immunization Program and inoculated intradermally at the left arm. Mycobacterium bovis [French (Pasteur) strain 1173-P2] with 1 mg/mL concentration is the vaccine type used in Iran (14).

2. Methods

Infants born from March to June 2017 that received a BCG vaccine at birth were enrolled in this prospective descriptive study. For this purpose, 12 health centers of Ahvaz (southwest Iran) were selected randomly. Infants referred to those health centers for routine health care were enrolled in the study and evaluated for BCG-associated complications. At first, a questionnaire including demographic data, gestational age, and BCG inoculation site was filled for each infant. The study cases were followed up for BCG complications at two, four, six, nine, and 12 months old by experienced health workers, and suspected cases were referred to pediatricians for confirmation and further evaluation. After explaining the study details to the children's parents, their written consent was taken. The Ethics Committee of Ahvaz Jundishapur University of Medical Sciences approved the study (code AJUMS.REC.1392.45). We used SSPS version 13.0 software for data analysis. The chi-square test was used for testing the statistical significance. A p value of less than 0.05 was considered statistically significant.

3. Results

The study enrolled 1506 infants (794 males and 712 females). The BCG vaccine was inoculated in the left arm in 1,091 (72.4%) infants and the right arm in 398 (26.4%) infants. Despite BCG vaccination, 17 (1.13%) infants showed no BCG scar. The BCG vaccine was inoculated in all infants in the first 27 days of birth (87% in the first three days). Four infants presented with significant injection site reactions. Totally, 106 (7.03%) lymphadenitis cases were detected, consisting of 66 (62%) males and 40 (38%) females. The lymphadenitis rate was significantly higher in males than in females (P = 0.024). The mean age at lymphadenitis presentation was 4.28 ± 0.79 months (Table 1). In 93 (87.7%) cases, lymphadenitis involved axillary nodes at the same site of vaccine inoculation. The other involvement sites included the supraclavicular lymph nodes in six (5.67%) cases and both the axillary and supraclavicular lymph nodes in seven (6.6%) cases.

Table 1.

Age Distribution at Bacillus Calmette-Guerin Lymphadenitis Presentation

Age (mo)No. (%)
249 (46.23)
2 - 434 (32.08)
4 - 612 (11.33)
6 - 99 (8.49)
9 - 122 (1.87)
Total 106 (100)

Fifty-three (50%) cases developed nonsuppurative lymphadenitis. Of them, 17 (16%) had complete resolution and 25 (23.5%) had partial resolution. In 11 (10.3%) cases, the lymph node size remained unchanged at 12 months of follow-up. Fifty-three (50%) cases developed suppurative lymphadenitis. Of them, 46 (43.4%) cases developed spontaneous drainage, and seven (6.6%) cases underwent needle aspiration (Table 2). Eighty-one cases of BCG inoculation in the left arm and 25 cases of BCG inoculation in the right arm developed lymphadenitis. There was no statistically significant difference between the site of BCG inoculation and the rate of lymphadenitis (P = 0.52).

Table 2.

Courses of Bacillus Calmette-Guerin Lymphadenitis in the 12-Month Follow-Up

CourseNo. (%)
Complete resolution17(16.04)
Partial resolution25 (23.58)
Unchanged11 (10.38)
Spontaneous drainage46 (43.40)
Needle aspiration7 (6.6)

In 202 infants, the gestational age was less than 37 weeks. Of them, 13 cases developed lymphadenitis. Lymphadenitis was observed in 93 cases with more than 37 weeks gestational age. The BCG lymphadenitis rate was not statistically significant between infants with different gestational ages (P = 0.83). After one year of follow-up, no other complications such as osteomyelitis or disseminated BCG infection were observed in our cases.

4. Discussion

Bacillus Calmette-Guerin vaccination is part of the routine immunization program in Iran and other developing countries, with an annual tuberculosis incidence of more than 1%. After injection, the BCG strain starts multiplying at the inoculation site and transfers to the regional lymph nodes via the lymphatic vessels. The vaccination site and the glandular response form a primary complex similar to natural tuberculosis infection (15). Some adverse reactions can occur following BCG vaccination, such as local ulceration, lymphadenitis, osteitis/osteomyelitis, and disseminated BCG disease (16). In our study, 17 (1.13%) cases showed no BCG scar, despite documented BCG vaccination. In a study, 5.6% of the cases had not no scar after BCG vaccination (17). The absence of a scar does not signify the lack of an effective immune response. In our study, lymphadenitis was prevalent in 7.03% of the cases. This proportion is relatively similar to a study from Iran as 5.6% (15) but higher than other reports from Iran 0.93% (18), France 0.1% (17), Latvia 0.1% (7), South Africa 0.5% (19), and Jamaica 1.9% (20).

The lymphadenitis incidence can be affected by several factors, including the virulence of BCG substrain, the viability of the final product, vaccine dose, age at vaccination, and administration technique (3, 4, 16, 19-23). In our study, the relatively high incidence of lymphadenitis can be due to the vaccine strain (Pasteur strain) (14, 24), age at vaccination (newborn infants), and improper administration techniques.

In the present study, 62% of BCG lymphadenitis cases were males. This finding is similar to some reports in which the lymphadenitis prevalence was higher in males than in females (18, 25, 26). However, some studies reported that the lymphadenitis prevalence was the same between males and females (15, 16). On average, in this study, lymphadenitis was presented at 4.28 months of age. In most studies, lymphadenitis developed within 2 - 6 months after birth (2, 15, 16, 23, 26-28). In our study, the commonest involved lymph node was the ipsilateral axillary node, followed by the supraclavicular lymph node. The regional distribution of lymphadenitis was similar to the reports of other studies (3, 7, 12, 15, 16, 23, 28). In our study, the suppurative and nonsuppurative lymphadenopathy rates were equal, similar to studies from the UK (5) and India (6). Other studies showed a higher rate of suppurative lymphadenitis (7, 11, 14, 23, 26). In our study, of 53 cases with nonsuppurative lymphadenitis, 17 resolved utterly, 25 regressed, and 11 remained unchanged after one year of follow-up. Of 53 cases with suppurative lymphadenitis, 46 ruptured spontaneously, and we approached needle aspiration in seven cases of a suppurative lymphadenitis. However, no surgical incision was needed. In our study, there was no statistically significant difference between the BCG inoculation sites, and the rate of lymphadenitis, but one study from Iran reported a higher rate of BCG lymphadenitis following intradermal injection in the right arm compared to the left arm (15).

This study has some limitations. First, we could not detect rare complications like osteomyelitis or disseminated infection because of only one year of follow-up and sample size. Second, we missed some cases with unchanged nonsuppurative lymphadenitis after one year of follow-up.

4.1. Conclusions

The relatively high incidence of BCG lymphadenitis in our region can be due to the vaccine strain, young vaccinees, and improper administration techniques. At least 50% of lymphadenitis cases following BCG vaccination consisted of nonsuppurative lymphadenitis, which is benign and regresses spontaneously without any treatment. However, suppurative lymphadenitis needs treatment. Needle aspiration should be used to prevent spontaneous rupture and sinus formation. Surgical excision is only rarely required.

References

  • 1.

    Pitt JM, Blankley S, McShane H, O'Garra A. Vaccination against tuberculosis: How can we better BCG? Microb Pathog. 2013;58:2-16. [PubMed ID: 23257069]. https://doi.org/10.1016/j.micpath.2012.12.002.

  • 2.

    Elsidig N, Alshahrani D, Alshehri M, Alzahrani M, Alhajjar S, Aljummah S, et al. Bacillus Calmette-Guerin vaccine related lymphadenitis in children: Management guidelines endorsed by the Saudi Pediatric Infectious Diseases Society (SPIDS). Int J Pediatr Adolesc Med. 2015;2(2):89-95. [PubMed ID: 30805444]. [PubMed Central ID: PMC6372430]. https://doi.org/10.1016/j.ijpam.2015.05.003.

  • 3.

    Goraya JS, Virdi VS. Bacille Calmette-Guerin lymphadenitis. Postgrad Med J. 2002;78(920):327-9. [PubMed ID: 12151684]. [PubMed Central ID: PMC1742390]. https://doi.org/10.1136/pmj.78.920.327.

  • 4.

    Bolger T, O'Connell M, Menon A, Butler K. Complications associated with the bacille Calmette-Guerin vaccination in Ireland. Arch Dis Child. 2006;91(7):594-7. [PubMed ID: 16547086]. [PubMed Central ID: PMC2082825]. https://doi.org/10.1136/adc.2005.078972.

  • 5.

    Venkataraman A, Yusuff M, Liebeschuetz S, Riddell A, Prendergast AJ. Management and outcome of Bacille Calmette-Guerin vaccine adverse reactions. Vaccine. 2015;33(41):5470-4. [PubMed ID: 26275478]. [PubMed Central ID: PMC4582770]. https://doi.org/10.1016/j.vaccine.2015.07.103.

  • 6.

    Moreira TN, Moraes-Pinto MI, Costa-Carvalho BT, Grumach AS, Weckx LY. Clinical Management of Localized Bcg Adverse Events in Children. Rev Inst Med Trop Sao Paulo. 2016;58:84. [PubMed ID: 27828625]. [PubMed Central ID: PMC5096638]. https://doi.org/10.1590/S1678-9946201658084.

  • 7.

    Engelis A, Kakar M, Meiksans R, Petersons A. BCG-SSI((R)) vaccine-associated lymphadenitis: Incidence and management. Medicina (Kaunas). 2016;52(3):187-91. [PubMed ID: 27496189]. https://doi.org/10.1016/j.medici.2016.05.001.

  • 8.

    Choi YY, Han MS, Lee HJ, Yun KW, Shin CH, Yoo WJ, et al. Mycobacterium bovis Osteitis Following Immunization with Bacille Calmette-Guerin (BCG) in Korea. J Korean Med Sci. 2019;34(1). e3. [PubMed ID: 30618511]. [PubMed Central ID: PMC6318445]. https://doi.org/10.3346/jkms.2019.34.e3.

  • 9.

    Rermruay R, Rungmaitree S, Chatpornvorarux S, Brukesawan C, Wittawatmongkol O, Lapphra K, et al. Clinical features and outcomes of Bacille Calmette-Guerin (BCG)-induced diseases following neonatal BCG Tokyo-172 strain immunization. Vaccine. 2018;36(28):4046-53. [PubMed ID: 29859799]. https://doi.org/10.1016/j.vaccine.2018.05.098.

  • 10.

    Baek SO, Ko HS, Han HH. BCG vaccination-induced suppurative lymphadenitis: four signs to pay attention to. Int Wound J. 2017;14(6):1385-7. [PubMed ID: 28425207]. [PubMed Central ID: PMC7949662]. https://doi.org/10.1111/iwj.12755.

  • 11.

    Bolursaz MR, Lotfian F, Velayati AA. Bacillus Calmette-Guerin vaccine complications in Iranian children at a University Hospital. Allergol Immunopathol (Madr). 2017;45(4):356-61. [PubMed ID: 28161281]. https://doi.org/10.1016/j.aller.2016.10.006.

  • 12.

    Govindarajan KK, Chai FY. BCG Adenitis-Need for Increased Awareness. Malays J Med Sci. 2011;18(2):66-9. [PubMed ID: 22135589]. [PubMed Central ID: PMC3216207].

  • 13.

    Naumeri F, Khan MS, Rauf A, Imran S, Tahir M. Role of needle aspiration and surgical excision in management of suppurative Bacillus Calmette Guerin lymphadenitis. J Pak Med Assoc. 2018;68(7):1120-3. [PubMed ID: 30317317].

  • 14.

    Mahmoudi S, Khaheshi S, Pourakbari B, Aghamohammadi A, Keshavarz Valian S, Bahador A, et al. Adverse reactions to Mycobacterium bovis bacille Calmette-Guerin vaccination against tuberculosis in Iranian children. Clin Exp Vaccine Res. 2015;4(2):195-9. [PubMed ID: 26273579]. [PubMed Central ID: PMC4524905]. https://doi.org/10.7774/cevr.2015.4.2.195.

  • 15.

    Behjati M, Ayat Elahi J. Post bcg lymphadenitis in vaccinated infants in Yazd, Iran. Iran J Pediatr. 2008;18(4):351-6.

  • 16.

    Pal S, Chakarabarti S, Phukan JP, Biswas S, Sinha A, Sinha R. Role of needle aspiration in diagnosis and management of suppurative bacille calmette-guerin adenitis: an institutional study of 30 cases. J Lab Physicians. 2015;7(1):21-5. [PubMed ID: 25949055]. [PubMed Central ID: PMC4411805]. https://doi.org/10.4103/0974-2727.154782.

  • 17.

    Dommergues MA, de La Rocque F, Guy C, Lecuyer A, Jacquet A, Guerin N, et al. Local and regional adverse reactions to BCG-SSI vaccination: a 12-month cohort follow-up study. Vaccine. 2009;27(50):6967-73. [PubMed ID: 19800440]. https://doi.org/10.1016/j.vaccine.2009.09.073.

  • 18.

    Barari-Savadkouhi R, Shour A, Masrour-Roudsari J. A study of the incidence of BCG vaccine complications in infants of Babol, Mazandaran (2011-2013). Caspian J Intern Med. 2016;7(1):48-51. [PubMed ID: 26958333]. [PubMed Central ID: PMC4761123].

  • 19.

    Jeena PM, Chhagan MK, Topley J, Coovadia HM. Safety of the intradermal Copenhagen 1331 BCG vaccine in neonates in Durban, South Africa. Bull World Health Organ. 2001;79(4):337-43. [PubMed ID: 11357213]. [PubMed Central ID: PMC2566397].

  • 20.

    Praveen KN, Smikle MF, Prabhakar P, Pande D, Johnson B, Ashley D. Outbreak of Bacillus Calmette-Guerin-associated lymphadenitis and abscesses in Jamaican children. Pediatr Infect Dis J. 1990;9(12):890-3. [PubMed ID: 2277745]. https://doi.org/10.1097/00006454-199012000-00007.

  • 21.

    Banani SA, Alborzi A. Needle aspiration for suppurative post-BCG adenitis. Arch Dis Child. 1994;71(5):446-7. [PubMed ID: 7826118]. [PubMed Central ID: PMC1030063]. https://doi.org/10.1136/adc.71.5.446.

  • 22.

    Teo SS, Smeulders N, Shingadia DV. BCG vaccine-associated suppurative lymphadenitis. Vaccine. 2005;23(20):2676-9. [PubMed ID: 15780451]. https://doi.org/10.1016/j.vaccine.2004.07.052.

  • 23.

    Suliman OM, Ahmed MJ, Bilal JA. Clinical characteristics and needle aspiration management of Bacillus Calmette-Guerin lymphadenitis in children. Saudi Med J. 2015;36(3):280-5. [PubMed ID: 25737168]. [PubMed Central ID: PMC4381010]. https://doi.org/10.15537/smj.2015.3.10294.

  • 24.

    Aelami MH, Alborzi A, Pouladfar G, Geramizadeh B, Pourabbas B, Mardaneh J. Post-Vaccination Disseminated Bacillus Calmette Guerin Infection Among Children in Southern Iran. Jundishapur J Microbiol. 2015;8(11). e25663. [PubMed ID: 26862381]. [PubMed Central ID: PMC4740899]. https://doi.org/10.5812/jjm.25663.

  • 25.

    Singla A, Singh S, Goraya JS, Radhika S, Sharma M. The natural course of nonsuppurative Calmette-Guerin bacillus lymphadenitis. Pediatr Infect Dis J. 2002;21(5):446-8. [PubMed ID: 12150189]. https://doi.org/10.1097/00006454-200205000-00026.

  • 26.

    Bukhari E, Alzahrani M, Alsubaie S, Alrabiaah A, Alzamil F. Bacillus Calmette-Guerin lymphadenitis: a 6-year experience in two Saudi hospitals. Indian J Pathol Microbiol. 2012;55(2):202-5. [PubMed ID: 22771644]. https://doi.org/10.4103/0377-4929.97869.

  • 27.

    Udgaonkar US, Patil SS, Rekha VB, Shah S. Suppurative supraclavicular bacille calmette-guerine lymphadenitis--a case report, awareness and management options. Indian J Med Microbiol. 2015;33 Suppl:137-9. [PubMed ID: 25657133]. https://doi.org/10.4103/0255-0857.150928.

  • 28.

    Santos A, Dias A, Cordeiro A, Cordinha C, Lemos S, Rocha G, et al. Severe axillary lymphadenitis after BCG vaccination: alert for primary immunodeficiencies. J Microbiol Immunol Infect. 2010;43(6):530-7. [PubMed ID: 21195982]. https://doi.org/10.1016/S1684-1182(10)60082-5.